Generation of Clinically Applicable CAR-NKT Cells Research Background Chimeric Antigen Receptor (CAR) T cell therapy has been approved by the Food and Drug Administration (FDA) for the treatment of B-cell malignancies and multiple myeloma. However, the use of autologous CAR-T cell products presents challenges such as high costs, long manufacturing ...

AAV-SB-CRISPR Screening Identifies Genetic Checkpoints in Tumor-Infiltrating Primary Natural Killer Cells for CAR-NK Therapy With the rapid advancement of biotechnology and gene editing technologies, increasing attention is being paid to enhancing the clinical potential of natural killer (NK) cells in cancer therapy. Despite their potential in clin...

Report: Intrinsic Role of m6A Reader Protein YTHDF2 in Regulating Tumor Immune Evasion Background Introduction In recent years, immunotherapy has become a hotspot in the field of tumor treatment, attracting attention for its ability to break through immune suppression barriers or enhance existing anti-tumor immunity. However, despite some successes...

Role of Syndecan Binding Protein (SDCBP) in Regulating Tumor Microenvironment, Tumor Progression, and Anti-PD1 Efficacy in Colorectal Cancer Background In recent years, immunotherapy has brought revolutionary advancements in cancer treatment. However, for colorectal cancer (CRC), anti-programmed cell death 1 (APD1) therapy shows relatively limited ...

Research Progress in Cancer Immunology: Tumor-derived Antigen Signals Induce CD8+ T-cell Exhaustion Localized to the Tumor Site Research Background and Purpose In recent years, immunotherapy has shown great potential in cancer treatment. However, tracking the behavior of immune cells after receiving antigen signals remains a challenge. Within tumor...